P Light
Overview
Explore the profile of P Light including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
29
Citations
231
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Senior P, Koh A, Yau J, Imes S, Dinyari P, Malcolm A, et al.
Diabet Med
. 2016 Apr;
34(2):204-212.
PMID: 27087519
Aims: Resuming insulin use due to waning function is common after islet transplantation. Animal studies suggest that gastrointestinal hormones, including gastrin and incretins may increase β-cell mass. We tested the...
2.
Benabid F, Light P, Couny F, Russell P
Opt Express
. 2009 Jun;
13(15):5694-703.
PMID: 19498571
We report a set of experimental observations on electromagnetically induced transparency in acetylene filled hollow-core photonic crystal fiber, involving both Lambda-type and V-type interactions over several lines of the R-branch...
3.
Light P
IDrugs
. 2005 Sep;
2(3):259-64.
PMID: 16160938
Nesiritide citrate is a human brain natriuretic peptide under development by Scios for the potential treatment of congestive heart failure (CHF). An NDA was submitted to the US FDA in...
4.
Light P
IDrugs
. 2005 Aug;
2(9):938-42.
PMID: 16121308
Pamicogrel is a cyclooxygenase inhibitor with platelet anti-aggregatory properties which is under development by Kanebo for chronic arterial occlusion. It also has potential in both prophylaxis and treatment of ischemic...
5.
Light P
IDrugs
. 2005 Jul;
3(12):1534-44.
PMID: 16037862
Azimilide is a class III anti-arrhythmic agent under development by Procter & Gamble. In December 1998, the company submitted an NDA with the FDA seeking an indication for the maintenance...
6.
Tokars J, Gehr T, Jarvis W, Anderson J, Armistead N, Miller E, et al.
Kidney Int
. 2001 Sep;
60(4):1511-6.
PMID: 11576366
Background: Vancomycin-resistant enterococci (VRE) are increasing in prevalence at many institutions, and are often reported in dialysis patients. We studied the prevalence of and risk factors for VRE at seven...
7.
Tokars J, Light P, Anderson J, Miller E, Parrish J, Armistead N, et al.
Am J Kidney Dis
. 2001 May;
37(6):1232-40.
PMID: 11382693
Vascular access infections are a major cause of morbidity and mortality in hemodialysis patients, and the use of antimicrobials to treat such infections contributes to the emergence and spread of...
8.
Honigman B, Lee J, Rothschild J, Light P, Pulling R, Yu T, et al.
J Am Med Inform Assoc
. 2001 Apr;
8(3):254-66.
PMID: 11320070
Objective: To evaluate the use of a computer program to identify adverse drug events (ADEs) in the ambulatory setting and to evaluate the relative contribution of four computer search methods...
9.
Honigman B, Light P, Pulling R, Bates D
Int J Med Inform
. 2001 Mar;
61(1):21-32.
PMID: 11248601
Introduction: In inpatients, computer monitors have been used to improve the detection of adverse drug events (ADEs). However, similar programs have not been available in outpatients. Objective: To describe an...
10.
Fink J, Blahut S, Reddy M, Light P
Am J Kidney Dis
. 2001 Feb;
37(2):348-55.
PMID: 11157377
Erythropoietin (EPO) is recommended in individuals progressing toward end-stage renal disease (ESRD) to correct anemia and its complications, which are common in this disease. This study evaluated the impact of...